DEF 14A: Alzamend Neuro Seeks Stockholder Approval for Key Proposals Including Reverse Stock Split and Nasdaq Compliance

Alzamend Neuro is holding its 2024 Annual Meeting of Stockholders virtually on April 30, 2024, to vote on key proposals including the election of directors, ratification of the independent auditor, approval of a common stock issuance related to a securities purchase agreement with Ault Lending, and a reverse stock split.

Summary

• Alzamend Neuro is convening its Annual Meeting of Stockholders on April 30, 2024, to be held virtually.
• Stockholders will vote on the election of eight directors, ratification of Baker Tilly US, LLP as the independent auditor, and approval of a common stock issuance related to a Securities Purchase Agreement with Ault Lending, LLC.
• The company is seeking approval to issue shares upon conversion of up to 6,000 shares of Series B preferred stock and exercise of warrants to purchase up to 6,000,000 shares of common stock, for a total purchase price of up to $6,000,000.
• A key proposal involves amending the Certificate of Incorporation to effect a reverse stock split of the common stock by a ratio of not less than one-for-two and not more than one-for-twenty, with the exact ratio determined by the Board of Directors before April 29, 2025.
• The Board recommends voting 'FOR' all proposals.

Sentiment

Score: 6

Explanation: The document is primarily informational, outlining the proposals for the annual meeting. While the reverse stock split and potential dilution carry negative implications, the company presents them as necessary steps for future growth and compliance. The overall sentiment is neutral to slightly positive.

Positives

• The proposed reverse stock split aims to increase the market price of the company's common stock, potentially enhancing its appeal to institutional investors and ensuring continued listing on the Nasdaq Capital Market.
• The company is actively seeking financing to conduct planned clinical trials and operations, and the agreement with Ault Lending provides a potential source of capital.
• The Board is actively engaged in corporate governance, with committees overseeing audit, compensation, and nominating/governance matters.

Negatives

• The issuance of shares to Ault Lending upon conversion or exercise of the SPA Securities will have a dilutive effect on existing stockholders, including the voting power and the economic rights of the existing stockholders.
• The availability for sale of a large amount of shares by Ault Lending may depress the market price of our Common Stock and, going forward, may impair our ability to raise additional capital through the public sale of our Common Stock.
• If Ault Lending purchases the full amount of the SPA Securities, Ault Lending would beneficially own in excess of 64% of the outstanding shares of our Common Stock as of the Execution Date (ignoring any limitations on conversion and/or exercise).

Risks

• Failure to obtain stockholder approval for the share issuance could jeopardize the funding agreement with Ault Lending.
• The reverse stock split may not achieve the desired increase in stock price, and the market price could decrease in the future.
• The company's reliance on related-party transactions, particularly with Ault Lending, could raise concerns about conflicts of interest.
• The company will need to raise significant cash financing to conduct its planned clinical trials and operations, and needs to increase its stockholders equity for purposes of Nasdaq continued listing requirements.

Future Outlook

The company anticipates needing to raise significant cash financing to conduct its planned clinical trials and operations and needs to increase its stockholders equity for purposes of Nasdaq continued listing requirements.

Management Comments

• Stephan Jackman, Chief Executive Officer, cordially invites stockholders to attend the Annual Meeting and emphasizes the importance of their vote.

Industry Context

The document does not provide explicit industry context, but the company's focus on clinical trials and Nasdaq listing suggests it operates within the biotechnology or pharmaceutical sector, where maintaining compliance and securing funding are critical.

Comparison to Industry Standards

• The document does not provide specific financial metrics for comparison.
• The document does not provide specific project metrics for comparison.
• The document does not provide specific results metrics for comparison.

Related Party Transactions

• The company has engaged in multiple transactions with entities affiliated with Milton C. Ault, III, including Ault Lending, Ault Alliance, ALSI, and ALSF.
• These transactions include securities purchase agreements, promissory notes, consulting agreements, and marketing agreements.
• The Board has adopted a policy requiring that future related-party transactions be on terms no less favorable to the company than could be obtained in arm's length transactions with independent third parties and be approved by a majority of disinterested outside directors.

Stakeholder Impact

• The reverse stock split could impact shareholders by potentially increasing the stock price and attracting institutional investors, but also carries the risk of price decline.
• The share issuance to Ault Lending will dilute existing shareholders' ownership.
• Employees and management are affected by the company's ability to secure funding for operations and clinical trials.

Next Steps

• Stockholders are encouraged to review the Proxy Statement and vote on the proposals.
• The Board will determine the exact ratio for the reverse stock split, if approved, before April 29, 2025.
• The company will proceed with the Securities Purchase Agreement with Ault Lending, pending stockholder approval.

Key Dates

Keywords

Alzamend Neuro, Annual Meeting, Proxy Statement, Reverse Stock Split, Ault Lending, Stock Issuance, Nasdaq, Board of Directors, Stockholder Approval, Series B Preferred Stock, Warrants, Dilution